Satoshi Ikeda

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto et al. · The Lancet Oncology · 2019 · 594 citations · Full text

Medicine, Pathology, Immune Checkpoint Inhibitor +5

<i>In situ</i> localization of <i>Propionibacterium acnes</i> DNA in lymph nodes from sarcoidosis patients by signal amplification with catalysed reporter deposition

Tetsuo Yamada, Yoshinobu Eishi, Satoshi Ikeda et al. · The Journal of Pathology · 2002 · 107 citations

Trabecular Bone Turnover and Bone Marrow Cell Development in Tail-Suspended Mice

Takeshi Sakata, Akinori Sakai, Hiroshi Tsurukami et al. · Journal of Bone and Mineral Research · 1999 · 99 citations · Full text

A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis

Satoshi Ikeda, Terufumi Kato, Hirotsugu Kenmotsu et al. · Journal of Thoracic Oncology · 2020 · 96 citations · Full text

Translational Medicine, Antibiotics, Pretreated Nsclc +5

Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated <i>EGFR</i>

Eisaku Miyauchi, Satoshi Morita, Atsushi Nakamura et al. · Journal of Clinical Oncology · 2022 · 89 citations · Full text